Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Evan Kharasch

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Anatomy

Concepts & Ideas

Area Under Curve

Physiology

Drug Interactions

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
30
Thummel, Kenneth
20
Hoffer, Christine
18
Sheffels, Pamela
18
Whittington, Dale
12
Hankins, DC
9
Walker, Alysa
8
Mautz, DS
6
Milgrom, Peter
6
Bowdle, Andrew
6
Spracklin, DK
5
Rooke, Alec
5
Schroeder, Jesara
5
Altuntas, Gul
5
Artru, Alan
5
Jubert, C

Sign-in to see all Coauthors

Publications

TOP 3
Pickrell Jacqueline E; Hosaka Kazuo; Jackson Douglass L; Heima Masahiro; Kharasch Evan; Milgrom Peter M
Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.
Montana Michael C; Cavallone Laura F; Stubbert Kristi K; Stefanescu Andrei D; Kharasch Evan D; Gereau Robert W
The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine.
Lanier William L; Kharasch Evan D
Contemporary clinical opioid use: opportunities and challenges.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Evan Kharasch (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Pickrell Jacqueline E; Hosaka Kazuo; Jackson Douglass L; Heima Masahiro; Kharasch Evan; Milgrom Peter M
Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.
Journal of clinical psychopharmacology 2009;29(5):426-31.
2009: Montana Michael C; Cavallone Laura F; Stubbert Kristi K; Stefanescu Andrei D; Kharasch Evan D; Gereau Robert W
The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine.
The Journal of pharmacology and experimental therapeutics 2009;330(3):834-43.
2009: Lanier William L; Kharasch Evan D
Contemporary clinical opioid use: opportunities and challenges.
Mayo Clinic proceedings. Mayo Clinic 2009;84(7):572-5.
2009: Kharasch Evan D; Subbarao Gowdahalli N; Cromack Keith R; Stephens Dennis A; Saltarelli Mario D
Sevoflurane formulation water content influences degradation by Lewis acids in vaporizers.
Anesthesia and analgesia 2009;108(6):1796-802.
2009: Kharasch Evan D; Walker Alysa; Whittington Dale; Hoffer Christine; Bedynek Pamela Sheffels
Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.
Drug and alcohol dependence 2009;101(3):158-68.
2009: Kharasch Evan D; Hoffer Christine; Whittington Dale; Walker Alysa; Bedynek Pamela Sheffels
Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.
Anesthesiology 2009;110(3):660-72.
2008: Kharasch E D; Bedynek P S; Walker A; Whittington D; Hoffer C
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
Clinical pharmacology and therapeutics 2008;84(4):506-12.
2008: Kharasch E D; Bedynek P S; Park S; Whittington D; Walker A; Hoffer C
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.
Clinical pharmacology and therapeutics 2008;84(4):497-505.
2008: Kharasch Evan D
Mutations in a molecule: the virtues of antagonism.
Mayo Clinic proceedings. Mayo Clinic 2008;83(10):1083-6.
2008: Lerman Jerrold; Kharasch Evan D; Eisenach James C; Warner Mark A; Jevtovic-Todorovic Vesna; Patel Piyush M; Sun Lena S
Journal-related and other special activities at the 2008 American Society of Anesthesiologists Annual Meeting.
Anesthesiology 2008;109(3):365.
2008: Kharasch E D
Adverse drug reactions with halogenated anesthetics.
Clinical pharmacology and therapeutics 2008;84(1):158-62.
2008: Ekins Sean; Iyer Manisha; Krasowski Matthew D; Kharasch Evan D
Molecular characterization of CYP2B6 substrates.
Current drug metabolism 2008;9(5):363-73.
2008: Coles Rebecka; Kharasch Evan D
Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
Pharmaceutical research 2008;25(6):1405-11.
2008: Kharasch Evan D; Mitchell Darain; Coles Rebecka; Blanco Roberto
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
Antimicrobial agents and chemotherapy 2008;52(5):1663-9.
2008: Kharasch Evan D; Mitchell Darain; Coles Rebecka
Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
Journal of clinical pharmacology 2008;48(4):464-74.
2008: Totah Rheem A; Sheffels Pamela; Roberts Toni; Whittington Dale; Thummel Kenneth; Kharasch Evan D
Role of CYP2B6 in stereoselective human methadone metabolism.
Anesthesiology 2008;108(3):363-74.
2008: Templeton I E; Thummel K E; Kharasch E D; Kunze K L; Hoffer C; Nelson W L; Isoherranen N
Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
Clinical pharmacology and therapeutics 2008;83(1):77-85.
2007: Kharasch E D; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Clinical pharmacology and therapeutics 2007;82(4):410-26.
2007: Coles Rebecka; Kharasch Evan D
Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;857(1):67-75.
2007: Feierman Dennis E; Trunfio Giuseppe; Morankar Anand; Kharasch Evan
More than polymorphism.
Anesthesia and analgesia 2007;104(6):1605; author reply 1605-6.
2007: Kharasch Evan D
Every breath you take, we'll be watching you.
Anesthesiology 2007;106(4):652-4.
2007: Totah Rheem A; Allen Kyle E; Sheffels Pamela; Whittington Dale; Kharasch Evan D
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
The Journal of pharmacology and experimental therapeutics 2007;321(1):389-99.
2006: Bruce R Douglas; McCance-Katz Elinore; Kharasch Evan D; Moody David E; Morse Gene D
Pharmacokinetic interactions between buprenorphine and antiretroviral medications.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43 Suppl 4():S216-23.
2006: Kirby Brian; Kharasch Evan D; Thummel Kenneth T; Narang Vishal S; Hoffer Christine J; Unadkat Jashvant D
Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.
Journal of clinical pharmacology 2006;46(11):1313-9.
2006: Kharasch Evan D; Schroeder Jesara L; Liggitt H Denny; Ensign Dustin; Whittington Dale
New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 2): Identification of nephrotoxic metabolites.
Anesthesiology 2006;105(4):737-45.
2006: Kharasch Evan D; Schroeder Jesara L; Liggitt H Denny; Park Sang B; Whittington Dale; Sheffels Pamela
New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 1): Identification of the nephrotoxic metabolic pathway.
Anesthesiology 2006;105(4):726-36.
2006: Lalovic Bojan; Kharasch Evan; Hoffer Christine; Risler Linda; Liu-Chen Lee-Yuan; Shen Danny D
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
Clinical pharmacology and therapeutics 2006;79(5):461-79.
2006: Kunze Kent L; Nelson Wendel L; Kharasch Evan D; Thummel Kenneth E; Isoherranen Nina
Stereochemical aspects of itraconazole metabolism in vitro and in vivo.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(4):583-90.
2006: Kharasch Evan D; Schroeder Jesara L; Bammler Theo; Beyer Richard; Srinouanprachanh Sengkeo
Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats.
Toxicological sciences : an official journal of the Society of Toxicology 2006;90(2):419-31.
2006: Jackson Douglass L; Milgrom Peter; Heacox Gail A; Kharasch Evan D
Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.
Journal of clinical psychopharmacology 2006;26(1):4-8.
2005: Kharasch Evan D; Schroeder Jesara L; Sheffels Pam; Liggitt H Denny
Influence of sevoflurane on the metabolism and renal effects of compound A in rats.
Anesthesiology 2005;103(6):1183-8.
2005: Chaobal Harshvardhan N; Kharasch Evan D
Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Clinical pharmacology and therapeutics 2005;78(5):529-39.
2005: Kharasch Evan D; Walker Alysa; Hoffer Christine; Sheffels Pamela
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Journal of clinical pharmacology 2005;45(10):1187-97.
2005: Kharasch Evan D; Thummel Kenneth E; Watkins Paul B
CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition.
Molecular interventions 2005;5(3):151-3.
2005: Klees Theresa Mariero; Sheffels Pamela; Thummel Kenneth E; Kharasch Evan D
Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.
Anesthesiology 2005;102(3):550-6.
2005: Klees Theresa Mariero; Sheffels Pamela; Dale Ola; Kharasch Evan D
Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(3):303-11.
2005: Dembo Gregory; Park Sang B; Kharasch Evan D
Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans.
Anesthesiology 2005;102(2):409-15.
2005: Kharasch Evan D; Walker Alysa; Hoffer Christine; Sheffels Pamela
Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Journal of clinical pharmacology 2005;45(1):79-88.
2005: Kharasch Evan D; Whittington Dale; Hoffer Christine; Krudys Kevin; Craig Keith; Vicini Paolo; Sheffels Pam; Lalovic Bojan
Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
Clinical pharmacokinetics 2005;44(7):731-51.
2004: Kharasch Evan D; Walker Alysa; Hoffer Christine; Sheffels Pamela
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Clinical pharmacology and therapeutics 2004;76(5):452-66.
2004: Dai Yang; Iwanaga Kazunori; Lin Yvonne S; Hebert Mary F; Davis Connie L; Huang Weili; Kharasch Evan D; Thummel Kenneth E
In vitro metabolism of cyclosporine A by human kidney CYP3A5.
Biochemical pharmacology 2004;68(9):1889-902.
2004: Whittington Dale; Sheffels Pam; Kharasch Evan D
Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;809(2):313-21.
2004: Sheffels Pam; Schroeder Jesara L; Altuntas T Gul; Liggitt H Denny; Kharasch Evan D
Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.
Chemical research in toxicology 2004;17(9):1177-89.
2004: Kharasch Evan D; Hoffer Christine; Whittington Dale; Sheffels Pamela
Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Clinical pharmacology and therapeutics 2004;76(3):250-69.
2004: Kharasch Evan D; Hoffer Christine; Whittington Dale
Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate.
Anesthesiology 2004;101(3):738-43.
2004: Kharasch Evan D; Whittington Dale; Hoffer Christine
Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.
Anesthesiology 2004;101(3):729-37.
2004: Dale Ola; Sheffels Pamela; Kharasch Evan D
Bioavailabilities of rectal and oral methadone in healthy subjects.
British journal of clinical pharmacology 2004;58(2):156-62.
2004: Kharasch Evan D; Mulroy Michael; Apfelbaum Jeffrey L
Toxicity during tumescent lipoplasty: a commentary.
Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery 2004;24(4):311-3.
2004: Kharasch Evan D; Hoffer Christine; Whittington Dale
The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
British journal of clinical pharmacology 2004;57(5):600-10.
2004: Altuntas T Gul; Park Sang B; Kharasch Evan D
Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A).
Chemical research in toxicology 2004;17(3):435-45.
2004: Kharasch Evan D; Hoffer Christine; Altuntas T Gul; Whittington Dale
Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl.
Journal of clinical pharmacology 2004;44(3):224-33.
2004: Kharasch Evan D
Perioperative COX-2 inhibitors: knowledge and challenges.
Anesthesia and analgesia 2004;98(1):1-3.
2003: Kharasch Evan D; Hoffer Christine; Whittington Dale; Sheffels Pam
Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
Clinical pharmacology and therapeutics 2003;74(6):543-54.
2003: Fitzgibbon Dermot; Morgan Donna; Dockter Deanna; Barry Chris; Kharasch Evan D
Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients.
Pain 2003;106(3):309-15.
2003: Altuntas T Gul; Zager Richard A; Kharasch Evan D
Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.
Toxicology and applied pharmacology 2003;193(1):55-65.
2003: Whittington Dale; Kharasch Evan D
Determination of morphine and morphine glucuronides in human plasma by 96-well plate solid-phase extraction and liquid chromatography-electrospray ionization mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;796(1):95-103.
2003: Emery Maurice G; Fisher Jeannine M; Chien Jenny Y; Kharasch Evan D; Dellinger E Patchen; Kowdley Kris V; Thummel Kenneth E
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.) 2003;38(2):428-35.
2003: Spracklin D K; Emery M E; Thummel K E; Kharasch E D
Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats.
Acta anaesthesiologica Scandinavica 2003;47(6):765-70.
2003: McIlroy David R; Kharasch Evan D
Acute intravascular volume expansion with rapidly administered crystalloid or colloid in the setting of moderate hypovolemia.
Anesthesia and analgesia 2003;96(6):1572-7, table of contents.
2003: Yao Caiping; Kunze Kent L; Trager William F; Kharasch Evan D; Levy René H
Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(5):565-71.
2003: Ibrahim Andra E; Feldman Jennifer; Karim Aziz; Kharasch Evan D
Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
Anesthesiology 2003;98(4):853-61.
2003: Kharasch Evan D; Hoffer Christine; Walker Alysa; Sheffels Pamela
Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
Clinical pharmacology and therapeutics 2003;73(3):199-208.
2002: Dale Ola; Hoffer Christine; Sheffels Pamela; Kharasch Evan D
Disposition of nasal, intravenous, and oral methadone in healthy volunteers.
Clinical pharmacology and therapeutics 2002;72(5):536-45.
2002: Conzen Peter F; Kharasch Evan D; Czerner Stephan F A; Artru Alan A; Reichle Florian M; Michalowski Piotr; Rooke G Alec; Weiss Branko M; Ebert Thomas J
Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency.
Anesthesiology 2002;97(3):578-84.
2002: Ibrahim Andra; Karim Aziz; Feldman Jennifer; Kharasch Evan
The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam.
Anesthesia and analgesia 2002;95(3):667-73, table of contents.
2002: Dale O; Hjortkjaer R; Kharasch E D
Nasal administration of opioids for pain management in adults.
Acta anaesthesiologica Scandinavica 2002;46(7):759-70.
2002: Gul Altuntas T; Kharasch Evan D
Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(2):148-54.
2002: Kharasch Evan D; Powers Karen M; Artru Alan A
Comparison of Amsorb, sodalime, and Baralyme degradation of volatile anesthetics and formation of carbon monoxide and compound a in swine in vivo.
Anesthesiology 2002;96(1):173-82.
2002: Ibrahim Andra; Park Sang; Feldman Jennifer; Karim Aziz; Kharasch Evan D
Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol.
Anesthesiology 2002;96(1):88-95.
2001: Phimmasone S; Kharasch E D
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Clinical pharmacology and therapeutics 2001;70(6):505-17.
2001: Altuntas T G; Kharasch E D
Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro.
Toxicology and applied pharmacology 2001;177(2):85-93.
2001: Lin Y S; Lockwood G F; Graham M A; Brian W R; Loi C M; Dobrinska M R; Shen D D; Watkins P B; Wilkinson G R; Kharasch E D; Thummel K E
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.
Pharmacogenetics 2001;11(9):781-91.
2001: Kharasch E D; Frink E J; Artru A; Michalowski P; Rooke G A; Nogami W
Long-duration low-flow sevoflurane and isoflurane effects on postoperative renal and hepatic function.
Anesthesia and analgesia 2001;93(6):1511-20, table of contents.
2001: Thummel K E; Brimer C; Yasuda K; Thottassery J; Senn T; Lin Y; Ishizuka H; Kharasch E; Schuetz J; Schuetz E
Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3.
Molecular pharmacology 2001;60(6):1399-406.
2001: Yao C; Kunze K L; Kharasch E D; Wang Y; Trager W F; Ragueneau I; Levy R H
Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.
Clinical pharmacology and therapeutics 2001;70(5):415-24.
2001: Ibrahim A E; Taraday J K; Kharasch E D
Bispectral index monitoring during sedation with sevoflurane, midazolam, and propofol.
Anesthesiology 2001;95(5):1151-9.
2001: Castillo J L; Milgrom P; Kharasch E; Izutsu K; Fey M
Evaluation of fluoride release from commercially available fluoride varnishes.
Journal of the American Dental Association (1939) 2001;132(10):1389-92; quiz 1459-60.
2001: Oda Y; Kharasch E D
Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.
The Journal of pharmacology and experimental therapeutics 2001;298(3):1021-32.
2001: Minoda Y; Kharasch E D
Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6).
Anesthesiology 2001;95(2):509-14.
2001: Tweedy C M; Milgrom P; Kharasch E D; Kaakko T; Spieker M; Coldwell S E
Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients.
Journal of clinical psychopharmacology 2001;21(3):268-72.
2001: Ibrahim A E; Ghoneim M M; Kharasch E D; Epstein R H; Groudine S B; Ebert T J; Binstock W B; Philip B K;
Speed of recovery and side-effect profile of sevoflurane sedation compared with midazolam.
Anesthesiology 2001;94(1):87-94.
2000: Manyike P T; Kharasch E D; Kalhorn T F; Slattery J T
Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation.
Clinical pharmacology and therapeutics 2000;67(3):275-82.
2000: Kharasch E D; Hankins D C; Fenstamaker K; Cox K
Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4.
European journal of clinical pharmacology 2000;55(11-12):853-9.
2000: Kharasch E D; Hankins D C; Taraday J K
Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(1):28-33.
1999: Kharasch E D; Jubert C
Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison.
Anesthesiology 1999;91(5):1267-78.
1999: Davis C L; Kausz A T; Zager R A; Kharasch E D; Cochran R P
Acute renal failure after cardiopulmonary bypass in related to decreased serum ferritin levels.
Journal of the American Society of Nephrology : JASN 1999;10(11):2396-402.
1999: Kharasch E D; Jubert C; Spracklin D K; Hoffman G M
Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats.
Toxicology and applied pharmacology 1999;160(1):49-59.
1999: Emery M G; Jubert C; Thummel K E; Kharasch E D
Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans.
The Journal of pharmacology and experimental therapeutics 1999;291(1):213-9.
1999: Kharasch E D; Jubert C; Senn T; Bowdle T A; Thummel K E
Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
Journal of clinical pharmacology 1999;39(7):664-9.
1999: Kharasch E D; Hankins D C; Jubert C; Thummel K E; Taraday J K
Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(6):717-23.
1999: Groudine S B; Fragen R J; Kharasch E D; Eisenman T S; Frink E J; McConnell S
Comparison of renal function following anesthesia with low-flow sevoflurane and isoflurane.
Journal of clinical anesthesia 1999;11(3):201-7.
1999: Kharasch E D; Hankins D C; Cox K
Clinical isoflurane metabolism by cytochrome P450 2E1.
Anesthesiology 1999;90(3):766-71.
1999: Kharasch E D; Mautz D; Senn T; Lentz G; Cox K
Menstrual cycle variability in midazolam pharmacokinetics.
Journal of clinical pharmacology 1999;39(3):275-80.
1998: Kharasch E D
[Compound A: toxicology and clinical relevance]
Der Anaesthesist 1998;47 Suppl 1():S7-10.
1998: Radant A D; Bowdle T A; Cowley D S; Kharasch E D; Roy-Byrne P P
Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;19(5):434-44.
1998: Baxter P J; Garton K; Kharasch E D
Mechanistic aspects of carbon monoxide formation from volatile anesthetics.
Anesthesiology 1998;89(4):929-41.
1998: Kharasch E D; Hankins D C; Baxter P J; Thummel K E
Single-dose disulfiram does not inhibit CYP2A6 activity.
Clinical pharmacology and therapeutics 1998;64(1):39-45.
1998: Kharasch E D; Hoffman G M; Thorning D; Hankins D C; Kilty C G
Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats.
Anesthesiology 1998;88(6):1624-33.
1998: Spracklin D K; Kharasch E D
Human halothane reduction in vitro by cytochrome P450 2A6 and 3A4: identification of low and high KM isoforms.
Drug metabolism and disposition: the biological fate of chemicals 1998;26(6):605-7.
1998: Ebert T J; Frink E J; Kharasch E D
Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers.
Anesthesiology 1998;88(3):601-10.
1998: Palmer R B; Mautz D S; Cox K; Kharasch E D
Endotracheal flumazenil: a new route of administration for benzodiazepine antagonism.
The American journal of emergency medicine 1998;16(2):170-2.
1998: Lochhead K M; Kharasch E D; Zager R A
Anesthetic effects on the glycerol model of rhabdomyolysis-induced acute renal failure in rats.
Journal of the American Society of Nephrology : JASN 1998;9(2):305-9.
1998: Coldwell S E; Kaufman E; Milgrom P; Kharasch E D; Chen P; Mautz D; Ramsay D S
Acute tolerance and reversal of the motor control effects of midazolam.
Pharmacology, biochemistry, and behavior 1998;59(2):537-45.
1998: Bowdle T A; Radant A D; Cowley D S; Kharasch E D; Strassman R J; Roy-Byrne P P
Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations.
Anesthesiology 1998;88(1):82-8.
1997: Freund P R; Bowdle T A; Posner K L; Kharasch E D; Burkhart V D
Cost-effective reduction of neuromuscular-blocking drug expenditures.
Anesthesiology 1997;87(5):1044-9.
1997: Ebert T J; Kharasch E D; Rooke G A; Shroff A; Muzi M
Myocardial ischemia and adverse cardiac outcomes in cardiac patients undergoing noncardiac surgery with sevoflurane and isoflurane. Sevoflurane Ischemia Study Group.
Anesthesia and analgesia 1997;85(5):993-9.
1997: Labroo R B; Paine M F; Thummel K E; Kharasch E D
Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(9):1072-80.
1997: Bowdle T A; Ready L B; Kharasch E D; Nichols W W; Cox K
Transition to post-operative epidural or patient-controlled intravenous analgesia following total intravenous anaesthesia with remifentanil and propofol for abdominal surgery.
European journal of anaesthesiology 1997;14(4):374-9.
1997: Kharasch E D; Russell M; Mautz D; Thummel K E; Kunze K L; Bowdle A; Cox K
The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
Anesthesiology 1997;87(1):36-50.
1997: Kharasch E D; Russell M; Garton K; Lentz G; Bowdle T A; Cox K
Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe.
Anesthesiology 1997;87(1):26-35.
1997: Kharasch E D; Frink E J; Zager R; Bowdle T A; Artru A; Nogami W M
Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity.
Anesthesiology 1997;86(6):1238-53.
1997: Lochhead K M; Kharasch E D; Zager R A
Spectrum and subcellular determinants of fluorinated anesthetic-mediated proximal tubular injury.
The American journal of pathology 1997;150(6):2209-21.
1997: Karl H W; Milgrom P; Domoto P; Kharasch E D; Coldwell S E; Weinstein P; Leroux B; Awamura K; Mautz D
Pharmacokinetics of oral triazolam in children.
Journal of clinical psychopharmacology 1997;17(3):169-72.
1997: Hankins D C; Kharasch E D
Determination of the halothane metabolites trifluoroacetic acid and bromide in plasma and urine by ion chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;692(2):413-8.
1997: Baxter P J; Kharasch E D
Rehydration of desiccated Baralyme prevents carbon monoxide formation from desflurane in an anesthesia machine.
Anesthesiology 1997;86(5):1061-5.
1997: Spracklin D K; Hankins D C; Fisher J M; Thummel K E; Kharasch E D
Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro.
The Journal of pharmacology and experimental therapeutics 1997;281(1):400-11.
1997: Kharasch E D; Thorning D; Garton K; Hankins D C; Kilty C G
Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats.
Anesthesiology 1997;86(1):160-71.
1997: Kharasch E D
Pharmacovigilance and safety aspects of sevoflurane.
Acta anaesthesiologica Scandinavica. Supplementum 1997;111():146-8.
1996: Spracklin D K; Thummel K E; Kharasch E D
Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(9):976-83.
1996: Kharasch E D; Sivarajan M
Gastroesophageal perforation after intraoperative transesophageal echocardiography.
Anesthesiology 1996;85(2):426-8.
1996: Spracklin D K; Kharasch E D
Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase.
Chemical research in toxicology 1996;9(4):696-702.
1996: Kharasch E D; Hankins D C
P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(6):649-54.
1996: Rooke G A; Ebert T; Muzi M; Kharasch E D
The hemodynamic and renal effects of sevoflurane and isoflurane in patients with coronary artery disease and chronic hypertension. Sevoflurane Ischemia Study Group.
Anesthesia and analgesia 1996;82(6):1159-65.
1996: Kharasch E D; Hankins D; Mautz D; Thummel K E
Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis.
Lancet 1996;347(9012):1367-71.
1996: Jin L; Davis M R; Kharasch E D; Doss G A; Baillie T A
Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane.
Chemical research in toxicology 1996;9(2):555-61.
1996: Mitra A K; Thummel K E; Kalhorn T F; Kharasch E D; Unadkat J D; Slattery J T
Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers.
Clinical pharmacology and therapeutics 1996;59(3):332-40.
1996: Kharasch E D
Metabolism and toxicity of the new anesthetic agents.
Acta anaesthesiologica Belgica 1996;47(1):7-14.
1995: Garton K J; Yuen P; Meinwald J; Thummel K E; Kharasch E D
Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(12):1426-30.
1995: Kharasch E D
Biotransformation of sevoflurane.
Anesthesia and analgesia 1995;81(6 Suppl):S27-38.
1995: Mitra A K; Thummel K E; Kalhorn T F; Kharasch E D; Unadkat J D; Slattery J T
Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo.
Clinical pharmacology and therapeutics 1995;58(5):556-66.
1995: Kharasch E D; Armstrong A S; Gunn K; Artru A; Cox K; Karol M D
Clinical sevoflurane metabolism and disposition. II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation.
Anesthesiology 1995;82(6):1379-88.
1995: Kharasch E D; Karol M D; Lanni C; Sawchuk R
Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics.
Anesthesiology 1995;82(6):1369-78.
1995: Jin L; Baillie T A; Davis M R; Kharasch E D
Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase.
Biochemical and biophysical research communications 1995;210(2):498-506.
1995: Labroo R B; Thummel K E; Kunze K L; Podoll T; Trager W F; Kharasch E D
Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(4):490-6.
1995: Kharasch E D; Hankins D C; Thummel K E
Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity.
Anesthesiology 1995;82(3):689-99.
1994: Labroo R; Kharasch E D
Gas chromatographic-mass spectrometric analysis of alfentanil metabolites. Application to human liver microsomal alfentanil biotransformation.
Journal of chromatography. B, Biomedical applications 1994;660(1):85-94.
1994: Mautz D S; Labroo R; Kharasch E D
Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry.
Journal of chromatography. B, Biomedical applications 1994;658(1):149-53.
1994: Kharasch E D; Thummel K E; Mautz D; Bosse S
Clinical enflurane metabolism by cytochrome P450 2E1.
Clinical pharmacology and therapeutics 1994;55(4):434-40.
1993: Kharasch E D; Thummel K E
Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane.
Anesthesiology 1993;79(4):795-807.
1993: Kharasch E D; Thummel K E; Mhyre J; Lillibridge J H
Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1.
Clinical pharmacology and therapeutics 1993;53(6):643-50.
1993: Kharasch E D; Thummel K E
Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?
Anesthesia and analgesia 1993;76(5):1033-9.
1993: Thummel K E; Kharasch E D; Podoll T; Kunze K
Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1.
Drug metabolism and disposition: the biological fate of chemicals 1993;21(2):350-7.
1992: Kharasch E D; Labroo R
Metabolism of ketamine stereoisomers by human liver microsomes.
Anesthesiology 1992;77(6):1201-7.
1992: Kharasch E D; Herrmann S; Labroo R
Ketamine as a probe for medetomidine stereoisomer inhibition of human liver microsomal drug metabolism.
Anesthesiology 1992;77(6):1208-14.
1992: Kharasch E D
Angiotensin-converting enzyme inhibitor-induced angioedema associated with endotracheal intubation.
Anesthesia and analgesia 1992;74(4):602-4.
1991: Kharasch E D; Hill H F; Eddy A C
Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism.
Anesthesiology 1991;75(3):520-4.
1991: Kharasch E D; Sivarajan M
Aerosol propellant interference with clinical mass spectrometers.
Journal of clinical monitoring 1991;7(2):172-4.
1991: Kharasch E D; Bowdle T A
Hypokalemia before induction of anesthesia and prevention by beta 2 adrenoceptor antagonism.
Anesthesia and analgesia 1991;72(2):216-20.
1989: Slattery J T; McRorie T I; Reynolds R; Kalhorn T F; Kharasch E D; Eddy A C
Lack of effect of cimetidine on acetaminophen disposition in humans.
Clinical pharmacology and therapeutics 1989;46(5):591-7.
1989: Kharasch E D; Yeo K T; Kenny M A; Amory D W
Influence of hypothermic cardiopulmonary bypass on atrial natriuretic factor levels.
Canadian journal of anaesthesia = Journal canadien d'anesthésie 1989;36(5):545-53.
1988: Kharasch E D; Yeo K T; Kenny M A; Buffington C W
Atrial natriuretic factor may mediate the renal effects of PEEP ventilation.
Anesthesiology 1988;69(6):862-9.
1988: Rooke G A; Kharasch E D
Left ventricular free wall rupture in acute myocardial infarction--a spectrum of severity.
Journal of cardiothoracic anesthesia 1988;2(2):218-22.

Sign-in to see more